Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$1.49MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Shankar Musunuri
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 116
- Beta
- 2.21
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -5.78
Financials
Revenue
$1.49M+3360.5%Net Income
$-24.88MEBITDA
$-19.82MFree Cash Flow
$-12.57MEPS (diluted)
$-0.07Shares Outstanding (diluted)
338.68M+152713.2%Operating Expenses
$17.93MCash & Debt
$100.05MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.41M | $-67.85M | $-0.23 |
| 2024 | $4.05M | $-54.05M | $-0.20 |
| 2023 | $6.04M | $-63.08M | $-0.26 |
| 2022 | $2.49M | $-86.80M | $-0.40 |
| 2021 | $0.00 | $-58.37M | $-0.30 |
| 2020 | $43.0K | $-21.82M | $-0.31 |
| 2019 | $0.00 | $-20.24M | $-1.53 |
| 2018 | $0.00 | $-8.64M | $-13.98 |
| 2017 | $0.00 | $-26.41M | $-69.91 |
| 2016 | $0.00 | $-16.21M | $-68.21 |
| 2015 | $0.00 | $-32.02M | $-145.22 |
| 2014 | $0.00 | $-22.79M | $-891.47 |
| 2013 | $8.0K | $-25.71M | $-120.93 |
| 2012 | $26.0K | $-16.93M | $-79.65 |
Valuation
OCGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (9)
- Newsglobenewswire.com·6d ago·Neutral
Ocugen to Participate in Upcoming Scientific Conferences MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific conferences.
View source ↗ - Newsglobenewswire.com·7d ago·Neutral
Ocugen to Participate in Upcoming October Investor and Industry Conferences MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that members of its executive leadership team will present at two upcoming investor and industry conferences.
View source ↗ - Newsglobenewswire.com·11d ago·Positive
…o Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa MALVERN, Pa., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that OCU400 has been granted provisional approval and priority designation from the LARTA Board, the regulatory agency responsible for reviewing and approving longevity and regenerative therapy programs within the Commonwealth of The B…
View source ↗ - Newsmarketbeat.com·20d ago·Negative
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances Ocugen NASDAQ: OCGN is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri said during a company discussion.
View source ↗ - Newsseekingalpha.com·24d ago·Neutral
Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical Ocugen is advancing three gene therapy programs—OCU400, OCU410ST, and OCU410—targeting major unmet needs in ophthalmology. I assign OCGN a Buy rating, citing strong clinical data, upcoming pivotal trial catalysts, and sufficient cash runway, despite high commercial and execution risk. Key upcoming catalysts include Phase 3 data for OCU400 and OCU410ST (Stargardt) in 2027 and a Phase 3 trial for OCU410 now FDA-cleared.
View source ↗ - Newszacks.com·33d ago·Neutral
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.
View source ↗ - Newsglobenewswire.com·35d ago·Positive
…ographic Atrophy Secondary to Dry Age-Related Macular Degeneration MALVERN, Pa., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410 (AAV5-hRORA), its first-in-class modifier gene therapy candidate for GA secondary to dry age-related macular degeneration (dAMD). The Company also hi…
View source ↗ - Newsglobenewswire.com·42d ago·Neutral
Ocugen to Participate in Upcoming September Investor and Industry Conferences MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in September 2026.
View source ↗ - Newsmarketbeat.com·51d ago·Neutral
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts Ocugen NASDAQ: OCGN is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in retinitis pigmentosa, Stargardt disease and geographic atrophy, Chairman, CEO and Co-Founder Shankar Musunuri said during a Canaccord discussion.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.06 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.07 vs $-0.05miss
- Tue, May 5$-0.06 vs $-0.05miss
- Wed, Mar 4$-0.06 vs $-0.06beat
- Wed, Nov 5$-0.07 vs $-0.06miss
- Fri, Aug 1$-0.05 vs $-0.06beat
- Fri, May 9$-0.05 vs $-0.06beat
Estimates and results for OCGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OCGN officers and directors.
- Bought
- $158k
- Sold
- $1.7m
4 trades
10 trades
- Musunuri Shankarsold
- Musunuri Shankarsold
- Johnson-greene Treerita Essalimabought
- Fernandes Prabhavathibought
- Castillo Kirstenbought
- Zhang Jungebought
- Musunuri Shankarsold
- Musunuri Shankarsold
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Dec 12, 2022 (34d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.